Trial Profile

An Investigator Initiated, Open Label, Randomized, Controlled, Multicentric Study, to assess the Safety and Efficacy of Nimotuzumab (BIOMAb-EGFR) concurrent with Cisplatin and Radiotherapy in histologically Documented Squamous Cell Carcinoma of the Cervix.

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 11 Oct 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

12 Sep 2017 Status changed from recruiting to active, no longer recruiting as per the results presented at the 42nd European Society for Medical Oncology Congress
12 Sep 2017 Results (n=74) assessing safety and efficacy at the end of 2 year presented at the 42nd European Society for Medical Oncology Congress
08 Feb 2010 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com